Cachexia - Pipeline Insight, 2022

DelveInsight’s, “Cachexia – Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Cachexia Understanding
Cachexia: Overview
Cachexia is a “wasting” disorder that causes extreme weight loss and muscle wasting, and can include loss of body fat. This syndrome affects people who are in the late stages of serious diseases like cancer, HIV or AIDS, COPD, kidney disease, and congestive heart failure (CHF). The term “cachexia” comes from the Greek words “kakos” and “hexis,” which mean “bad condition.”
There are three main categories of cachexia:
Precachexia is defined as a loss of up to 5 percent of your body weight while having a known illness or disease. It’s accompanied by appetite loss, inflammation, and changes in metabolism.
Cachexia is a loss of more than 5 percent of your body weight over 12 months or less, when you’re not trying to lose weight and you have a known illness or disease. Several other criteria include loss of muscle strength, decreased appetite, fatigue, and inflammation.
Refractory cachexia applies to individuals with cancer. It is weight loss, muscle loss, loss of function, plus a failure to respond to cancer treatment.
There is no specific treatment or way to reverse cachexia. The goal of treatment is to improve symptoms and quality of life. Cachexia can be very serious. It can complicate treatment for the condition that caused it and lower response to that treatment. People with cancer who have cachexia are less able to tolerate chemotherapy and other therapies they need to survive.

Cachexia Emerging Drugs Chapters
This segment of the Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cachexia Emerging Drugs
Macimorelin: AEterna Zentaris
Macimorelin (AEZS 130) is an orally active, small-molecule, being developed by AEterna Zentaris for the diagnosis of adult and pediatric growth hormone deficiency and for the treatment of cachexia associated with chronic diseases, such as AIDS and cancer. Macimorelin was approved by the FDA in December 2017 under the market name Macrilen for oral solution. Macimorelin stimulates GH release by activating growth hormone secretagogue receptors present in the pituitary and hypothalamus. The drug is currently being investigated in Phase II clinical to treat patients with Cancer Cachexia.
PF- 06946860: Pfizer
PF- 06946860 is a Growth Factor Blocker being investigated in Phase I stage of development. A 6 week double blind study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite has been initiated to find out how participants with advanced cancer and anorexia feel after receiving repeated doses injected under the skin.
Further product details are provided in the report……..
Cachexia: Therapeutic Assessment
This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Cachexia
There are approx. 15+ key companies which are developing the therapies for Cachexia. The companies which have their Cachexia drug candidates in the mid to advanced stage, i.e. Phase II include, AEterna Zentaris.
Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Late-stage products (Phase III )
Mid-Stage products (Phase II)
Early-stage products ( Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Oral
Molecule Type

Products have been categorized under various Molecule types such as
Small molecules
Peptide
Antibiotics
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cachexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cachexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cachexia drugs.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cachexia.

Cachexia Report Insights
Cachexia Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Cachexia Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Cachexia drugs?
How many Cachexia drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cachexia?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cachexia therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Cachexia and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
GlaxoSmithKline
AEterna Zentaris
AVEO Pharmaceuticals, Inc.
NGM Biopharmaceuticals
Pfizer
Endevica Bio
Aphios coporation
Actimed therapeutics
TMS Co., Ltd.
CatalYm GmbH
Green Cross Wellbeing
ImmunoForge
Faraday Pharmaceuticals
Immuneering

Key Products
GSK2881078
Macimorelin
AV-380
NGM120
PF-06946860
TCMCB07
APH-0802
ACM-001
TMS-008
CTL-002
GCWB 204
ACM-002
PF-1801

Companies

GlaxoSmithKline
AEterna Zentaris
AVEO Pharmaceuticals, Inc.
NGM Biopharmaceuticals
Pfizer
Endevica Bio
Aphios coporation
Actimed therapeutics
TMS Co., Ltd.
CatalYm GmbH
Green Cross Wellbeing
ImmunoForge
Faraday Pharmaceuticals
Immuneering